Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
P Pérez-Wert, A Custodio, P Jimenez-Fonseca… - Gastric Cancer, 2024 - Springer
Background Gastroesophageal adenocarcinoma in young adults (GCYA) counts for 10–
15% of diagnoses. Previous studies have mainly focused on surgical outcomes in patients …
15% of diagnoses. Previous studies have mainly focused on surgical outcomes in patients …
[HTML][HTML] Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
J Hernando, M Roca-Herrera, A García-Álvarez… - European Journal of …, 2023 - Elsevier
Purpose There is an increasing interest in the role of sex and gender in cancer patients. The
impact of sex differences in oncological systemic therapies is still unknown, and there is a …
impact of sex differences in oncological systemic therapies is still unknown, and there is a …
Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study
P García-Alfonso, P Jimenez-Fonseca… - The …, 2024 - academic.oup.com
Abstract Introduction The initial SARS-CoV-2 pandemic wave in Spain in 2020 precipitated
significant paradigm shifts in gastrointestinal oncology patient management. This study …
significant paradigm shifts in gastrointestinal oncology patient management. This study …
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab …
P Jimenez-Fonseca, V Foy, S Raby… - … in medical oncology, 2023 - journals.sagepub.com
Background: Trastuzumab and chemotherapy is the standard first-line treatment in human
epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer …
epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer …
CO160 Burden of Illness and Treatment Patterns of Adult Patients with Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer: A Systematic Literature …
Z Chen, J Ajani, A Yusuf, C Eichinger… - Value in …, 2023 - valueinhealthjournal.com
Objectives Gastric and gastroesophageal junction cancer (G/GEJC), represents the fifth most
common malignancy and the fourth leading cause of cancer-related death worldwide. This …
common malignancy and the fourth leading cause of cancer-related death worldwide. This …
Estudio de la supervivencia global y de los factores pronósticos del cáncer gástrico localizado tratado de forma radical en el Hospital Parc Taulí de Sabadell entre los …
I Macias Declara - 2023 - ddd.uab.cat
Estudio observacional, unicéntrico, retrospectivo de los pacientes afectos de cáncer gástrico
no metastásico, tratados con intención radical en el Hospital Parc Taulí de Sabadell desde …
no metastásico, tratados con intención radical en el Hospital Parc Taulí de Sabadell desde …